Pharmaceutical Business Review Latest News News Archive
Latest news from Pharmaceutical Business Review
http://www.pharmaceutical-business-review.com/rss/rss_features.asp
Page: 2 of 40 
- Foamix begins phase II athlete's foot trial
- Amarin agrees Huntington's trial design with FDA
- Intradigm study shows effectiveness of RNAis in SARS
- Pfizer gets European approval for breast cancer drug
- Novavax and Wave Biotech enter flu vaccine alliance
- Alnylam and Isis secure rights to potential hepatitis treatments
- CVBT to begin clinical trial into diabetic wounds
- Pharmacyclics commences trial of drug to treat brain metastases
- CuraGen and TopoTarget initiate phase Ib ovarian cancer trial
- Inovio receives $1 million US defense grant for DNA vaccinations
- Eisai seeks FDA approval for epilepsy drug
- Nabi receives grant for nicotine addiction treatment
- Cephalon gets US OK for sugar-free cancer pain medicine
- Merck to buy equity in Geron
- Medarex licenses antibody development system to ImClone
- Ambion and Rosetta Genomics collaborate over microRNA molecules
- FDA committee rejects Abbott's Xinlay
- Clues to movement disorders found in mice
- FDA approves amended label for ParaGard
- Green light for Barr's generic arthritis drug
- MedImmune to purchase Cellective Therapeutics
- Unigene receives $4 million milestone for Fortical approval
- Pfizer completes $1.9 billion acquisition of Vicuron
- GTx given FDA recommendations for pivotal prostate cancer trial
- Bayer and Onyx kidney cancer drug given FDA priority
- OSI's Tarveca gets recommendation for pancreatic cancer
- Neurochem launches European trial of Alzheimer's drug
- Pfizer's osteoporosis drug application rejected by FDA
- Novogen drug found to reduce cardiovascular risk
- Fast track status for DVC biodefense vaccine development
- Ceragenix's eczema cream shows promise
- Sanofi drug proves effective in combination cancer treatment
- Forbes' cholesterol drug performs well in preclinical studies
- GlaxoSmithKline's Arranon gains backing of FDA panel
- BMS drug proves effective against arthritis
- Dov initiates new bicifadine trial in back pain
- Dendreon to seek FDA approval for prostate cancer treatment
- Impax and Mylan both gain approval for generic diabetes drug
- Vical receives grant to develop flu vaccine
- UCB plans to market new epilepsy drug in Europe
- Adolor begins trial of sterile pain patch
- Erbitux gains Canadian approval
- Scientists describe protien that powers cell movement
- Adult ADHD population on the increase
- Advancis to conduct further Pulsys trial
- PRA to manage clinical trial for Biomira cancer vaccine
- Genzyme tests treatment for rare genetic disease
- Alkermes schizophrenia treatment gains Italian approval
- Microbia starts study of novel cholesterol treatment
- pSivida gets new manufacturing plant
- Cangene awarded UK contract to supply smallpox vaccine
- Medivation purchases promising anti prostate cancer compounds
- Encouraging study for ReceptoPharm's HIV drug
- Centocor's inflammation drug given approval for new indication
- Ranbaxy given tentative approval for overactive bladder treatment
- Pfizer eye drug gets European recommendation
- Study suggests Javelin painkiller more effective than Voltarol
- Positive preclinical test for Transition's diabetes drug
- Viventia's phase II head and neck cancer trial given FDA approval
- StemCells files amendment to study application
- AstraZeneca's breast cancer drug gets FDA green light
- St Jude researchers identify a cause of obesity
- Walgreens acquires rights to Theragran-M multivitamins
- ViaCell suspends study after patient complications
- Setback for GSK in new HIV drug development
- Barrier Therapeutics acne treatment performs well in study
- Study suggests potential of stem cells in spinal cord injuries
- Poor results for Axonyx Alzheimer's drug
- Pfizer receives FDA non-approvable letter for parecoxib
- Vion begins phase II anticancer drug trial
- MDS Nordion supplies isotope for lymphoma treatment
- Isis cholesterol-lowering drug enters phase II
- Celera initiates study of drug to treat psoriasis
- Celtic Pharma pays $48 million for cancer drug
- Nabi begins test of hospital-acquired infections treatment
- Evolutec posts positive trial results for hay fever drug
- Siga to collaborate with St Louis University over smallpox drug
- AlphaRx produces new antibiotic formulation
- Somaxon begins enrolling in insomnia study
- Positive study results for Novartis blood pressure drug
- New study reinforces value of beta blockers in heart failure patients
- FDA requests more information on Avanir drug
- Solid early trial for Neurogen's insomnia treatment
- Vical receives grant to investigate rapid vaccine development
- Illumina and GSK in research collaboration
- Archemix and Nuvelo halt development of anticoagulant candidate
- Genaera commences study of cystic fibrosis drug
- FDA fast tracks Medicure's heart drug
- Abmaxis and MaimoniDex to develop arthritis drug
- Pfizer's Lyrica distributed in US
- Exelixis starts cancer trials for three new compounds
- Oxford University and GE Healthcare in cancer collaboration
- Vitro Diagnostics and BioCare form strategic alliance
- Genaissance and Otsuka collaborate over genetic marker discovery
- Ceregene initiates gene therapy trial in Parkinson's
- First patients enrolled in Bioenvision's breast cancer study
- Alexion completes enrollment in blood disorder trial
- Gentium's anti-cancer sensitizing agent to begin clinical tests
- WHO develops anti epidemic strategy in Asia Pacific
- Tarceva given European approval for treatment of lung cancer